Browse by Medical Category
Accepting New Patients
Dr. Fasano sees pediatric and adult patients at the Center for Celiac Research and Treatment.
Go To Programs
MassGeneral Hospital for Children
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
World-renowned pediatric gastroenterologist, research scientist and entreprenuer Dr. Alessio Fasano is chief of Pediatric Gastroenterology and Nutrition at MassGeneral Hospital for Children (MGHfC). Dr. Fasano directs the Center for Celiac Research, specializing in the treatment of patients of all ages with gluten-related disorders, including celiac disease, wheat allergy and gluten sensitivity. He treats patients with acute and chronic diarrheal diseases, and treats infants and children who have difficult-to-treat gastrointestinal problems.
Dr. Fasano also directs the Mucosal Immunology and Biology Research Center and is associate chief for Basic, Clinical and Translational Research. Under his leadership, investigators are studying the molecular mechanisms of autoimmune disorders including celiac disease, and other-gluten-related disorders. He has been named visiting professor of pediatrics at Harvard Medical School. He authored the groundbreaking study in 2003 that established the rate of celiac disease at one in 133 Americans. Widely sought after by national and international media, Dr. Fasano has been featured in hundreds of interviews including outlets such as The New York Times, The Wall Street Journal; National Public Radio; CNN; Bloomberg News, and others.
Dr. Fasano is director of the Mucosal Immunology and Biology Research Center at MassGeneral Hospital for Children. Dr. Fasano's research established that celiac disease affects approximately 1 percent of the U.S. population, a significantly higher number than previously believed, and helped define gluten sensitivity as a condition on the spectrum of gluten-related disorders. His research also uncovered the role that impairment of the tight junctions between intestinal enterocytes plays in the development of celiac disease.
During research designed to develop a cholera vaccine, Dr. Fasano uncovered a toxin, zonula occludens, which causes diarrhea by loosening the tight junctions and allowing intestinal permeability. Subsequently, he identified the protein zonulin, which controls this process. He has since established the role of zonulin in the pathogenesis of a number of autoimmune diseases, including celiac disease, type 1 diabetes, and certain cancers and diseases of the nervous system.
View my most recent publications at PubMed
In pursuit of a novel tool for the research and treatment of celiac disease, scientists at the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital have validated the use of intestinal organoids.
Researchers at MassGeneral Hospital for Children have discovered novel genes and pathways related to early stages in the development of celiac disease and the ongoing inflammation and comorbidities associated with the condition.
Researchers at MassGeneral Hospital for Children have been selected to receive a grant of $1.5 million from the European Commission as part of an international consortium to study the role of the gut microbiome in autism spectrum disorders.
With the help of genetically engineered mice, scientists at the Massachusetts General Hospital are moving closer to establishing the role that increased intestinal permeability, sometimes called a "leaky gut," plays in chronic inflammatory conditions.
A Massachusetts General Hospital study finds reduced expression of genes involved in integrity of the blood-brain barrier, intestinal barrier in those with autism spectrum disorder.
Research at the MGH is interwoven throughout more than 30 departments, centers and units, and is conducted with the support and guidance of the MGH Research Institute. The Research Roundup is a monthly series highlighting studies, news and events.
For the Celiac Center for Research and Treatment, this coming January marks 20 years of research breakthroughs and patient care and four years since moving to Boston. Alessio Fasano, MD, director of the Celiac Center, reflects on his team's accomplishments over the past two decades and the high standard of care he delivers to patients every day.
In surprising findings, researchers from MassGeneral Hospital for Children and Boston Children’s Hospital have discovered that nearly one in five children with celiac disease sustained persistent intestinal damage, despite strict adherence to a gluten-free diet.
MassGeneral Hospital for Children is being recognized as a collaborative partner with Mead Johnson Nutrition in the National Microbiome Initiative, announced by the White House Office of Science and Technology Policy.
Alessio Fasano, MD, is named first incumbent of the W. A. Walker, MD Endowed Chair in Pediatric Gastroenterology and Nutrition.
An study led by investigators at the MGHfC Center for Celiac Research and Treatment finds that neither breastfeeding nor delaying the introduction of gluten-containing foods prevents or delays the development of celiac disease in at-risk children.
Celiac patients and other consumers trying to sort the gluten-free from the gluten-filled, will have an easier time after August 5, when the FDA standards for gluten-free labeling go into effect.
Maureen Leonard, MD, is looking for 500 newborns at risk for celiac disease. The third-year Mass General Hospital for Children (MGHfC) Pediatric Gastroenterology fellow is working with Alessio Fasano, MD, director of the Center for Celiac Research and division chief of Pediatric Gastroenterology and Nutrition at MGHfC.
In this news segment with Dr. Mallika Marshall from WBZ-TV Boston, Dr. Alessio Fasano, joined by patient Sharone Jelden, talks about diagnosis and treatment for celiac disease and who benefits from following a gluten-free diet.
Overuse of popular NSAIDs is associated with intestinal permeability, which is a condition associated with celiac disease and other autoimmune disorders. Dr. Alessio Fasano, director of the Center for Celiac Research at MassGeneral Hospital for Children, discusses the implications of using popular pain medication in relation to gluten-related disorders and exercise.
People with celiac disease and other gluten-related disorders soon will have something to celebrate with the recent launch of the Celiac Program at Harvard Medical School. Advancing basic and clinical research is the main goal of the partnership of experts in celiac care from Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Boston Children’s Hospital, along with collaboration in clinical and training initiatives.
In a long-awaited step toward accurate gluten-free food labeling, the U.S. Food and Drug Administration (FDA) has released its definition of “gluten free” to be used by food manufacturers.
The FDA has released its definition of "gluten free" to be used by food manufacturers. The long-awaited regulations stem from research conducted by the Center for Celiac Research.
Dr. Alessio Fasano, director of the Center for Celiac Research at MassGeneral Hospital for Children, separates the myths from the realities about the gluten-free diet in this video with Huffington Post science editor Jacqueline Howard.
Transcending the disciplines of microbiology, molecular and cell biology, and physiology, Dr. Alessio Fasano’s research focuses on the mucosal biology of the gut. By focusing on the “cross talk” between enteric pathogens and their hosts, Dr. Fasano’s group has elucidated various organs and cell functions involved in health and disease, including inflammatory and autoimmune disorders.
Calling for action on the final steps before implementation of safe gluten-free labeling regulations, Dr. Alessio Fasano joined Rep. Nita Lowey (D-NY) in an Op-Ed published in the Huffington Post Healthy Living section on April 3.
Back to Top